Aptamers based targeted drug delivery system: A newer trend in cancer treatment therapy

---

Review Article

Author Details : Paramita Dey*, Anushmita Ghosh, Subhrajit Sarker

Volume : 11, Issue : 2, Year : 2023

Article Page : 97-104

https://doi.org/10.18231/j.jpbs.2023.016

Suggest article by email

Get Permission

---

Abstract

The investigation of targeted drug delivery systems as a way to improve therapeutic efficacy while minimizing adverse effects is a result of the development of novel cancer treatment strategies. This subject explores the exciting field of aptamer-based targeted drug delivery systems for the treatment of cancer. Short single-stranded DNA or RNA molecules called aptamers have a remarkable capacity to bind to particular target molecules with high specificity and affinity. Aptamers have drawn attention as excellent possibilities for creating targeted drug delivery systems by taking use of their special characteristic. The applications, choice, and modification of aptamers to precisely identify cancer-associated biomarkers, such as receptors overexpressed on cancer cells, are covered in detail in this topic. Additionally, it emphasizes various techniques for aptamer-drug conjugation optimization which ensure effective carrier delivery and regulated drug release inside the tumor microenvironment. It is investigated if aptamer-based systems have the ability to overcome problems such drug resistance, heterogeneity, and insufficient drug penetration within solid tumors.In conclusion, this article illuminates how aptamer-based targeted drug delivery systems have transformed the world of cancer treatment. It advances knowledge of these systems and their potential to transform cancer treatment by providing insights into design principles, delivery systems, and therapeutic results.

Keywords: Cancer, Cancer treatment, Aptamer, SELEX, Target delivery, Conjugate

How to cite : Dey P, Ghosh A, Sarker S, Aptamers based targeted drug delivery system: A newer trend in cancer treatment therapy. J Pharm Biol Sci 2023;11(2):97-104

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.